1 / 14

Getting the best treatment to the most people possible

Getting the best treatment to the most people possible. Enabling policies: threats & opportunities MSF Access Campaign. Funding crisis . Impact on rt to health - not universal but rationed Impact on second-line and reluctance to bring in newer (better) treatment into first line

knoton
Download Presentation

Getting the best treatment to the most people possible

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Getting the best treatment to the most people possible Enabling policies: threats & opportunities MSF Access Campaign

  2. Funding crisis • Impact on rt to health - not universal but rationed • Impact on second-line and reluctance to bring in newer (better) treatment into first line • Starting with TDF but going forward with integrase inhibitors • Particularly acute for middle income countries • Danger of losing community monitoring • Funding crisis for organisations who work on IP barriers

  3. Neglected co-infectionsAmong patients with AIDS, chronic HCV infection is associated with a 50% increase in mortality Hepatitis treatment for co-infected patientsReluctance to treat, price and regulatory issues

  4. WTO Middle income countries Low income countries Big issue of 2016 implementation deadline for product patents LDCs to introduce product patents, need for extension NOT COUNTRY BY COUNTRY BUT ALL LDCs Issue of OAP and ARIPO just registering patents even before deadline Fencing in middle income developing countries Mis-use (ever-greening to obtain patents on older patents in MICs Less freedom to operate for generics undermines production Access – treatment available in LDCs not available in MICs

  5. e.g. Linezolid patent in SA R676 per tablet in private sector (MSF price); R264 per tablet in public sector (available for R9.9 from Cipla) MSF wanting to use for patients failing DR-TB Up to R108,000 per patient (6 months) Basic patent until 2014; crystalized form II patent until 2022 (will block entry?)

  6. Ever-greening Rejections due to local examination and application of strict patentability criteria Credit for this particular slide: Lawyers Collective HIV/AIDS Unit, India

  7. NOVARTIS Novartis DROP the case kick off the campaign – protests timed with the court hearings to maintain public attention.

  8. Growing movement – SA, Thailand, Argentina, Philippines - Examination system weeds out patent applications that should not be granted. Direct benefit with earlier expiry of patents on ARVs. Compulsory licensing China - key announcement of procedures India – applications by generic competitors South Africa – reforms needed

  9. Why do we care? :

  10. US and EU FTA negotiations expanding and now reaching a very crucial stage 2nd Udyog Bhavan protest Oct 2010: Comment posted "I have never seen so many police people with batons and guns.“ http://www.bbc.co.uk/news/health-11488711

  11. VLs Threats or Opportunities“Creating generic monopolies” • New business model – exclude middle income countries • Do we know enough – secret deals • Shrinking access even for Indian patients • Conditions that block API (raw materials) access • Undermine CLs • Generics have to keep out of markets where there are no patent barriers • Venezuela: no patents granted, only applications filed. BILATERAL DEALS GETTING WORSE.

  12. What we can do • Start Hep C treatment in some countries • Getting educated on new drugs • Patent oppositions on new drugs to prevent long monopolies - CLs needed for MICs - Defend India’s law - SA ‘Fix the Patent Law’ Campaign crucial - STOP the FTAs - VLs cannot be ignored

More Related